Target Mediated Disposition (TMD) Model Based Dose Selection for Fixed SC Doses of Anti-MAdCAM-1 Monoclonal Antibody (PF-00547659) in Crohnʼs Disease
William Sandborn, Gail M. Comer(Pfizer (United States)), Fabio Cataldi(Pfizer (United States)), Jason G. Williams(National Institute of Environmental Health Sciences)
Cited by 0
Related Papers
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
|The Lancet|2023|350
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
|The Lancet|2017|198
Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions
|Journal of Biological Chemistry|2000|112